Response to Severe Acute Respiratory Syndrome Coronavirus 2 Initial Series and Additional Dose Vaccine in Patients With Predominant Antibody Deficiency

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in patients with predominant antibody deficiency (PAD) is associated with high morbidity, yet data regarding the response to SARS-CoV-2 immunization in PAD patients, including additional dose vaccine, are limited. OBJ...

Descripción completa

Detalles Bibliográficos
Autores principales: Barmettler, Sara, DiGiacomo, Daniel V., Yang, Nancy J., Lam, Tiffany, Naranbhai, Vivek, Dighe, Anand S., Burke, Kristin E., Blumenthal, Kimberly G., Ling, Morris, Hesterberg, Paul E., Saff, Rebecca R., MacLean, James, Ofoman, Onosereme, Berrios, Cristhian, St Denis, Kerri J., Lam, Evan C., Gregory, David, Iafrate, Anthony John, Poznansky, Mark, Lee, Hang, Balazs, Alejandro, Pillai, Shiv, Farmer, Jocelyn R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Academy of Allergy, Asthma & Immunology 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976568/
https://www.ncbi.nlm.nih.gov/pubmed/35381395
http://dx.doi.org/10.1016/j.jaip.2022.03.017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976568/
https://www.ncbi.nlm.nih.gov/pubmed/35381395
http://dx.doi.org/10.1016/j.jaip.2022.03.017

Ejemplares similares